Combined Tumor Infiltrating Lymphocytes and PD ‐ L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Head & Neck · 2025
DOI: 10.1002/hed.28128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Catherine T Haring und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, B7-H1 Antigen, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objectives
To determine if the assessment of CD8+ tumor‐infiltrating lymphocytes (TILs) adds prognostic information to the PD‐L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Methods
A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre‐treatment biopsies, CD8+ TILs and PD‐L1 CPS were quantified on a tissue microarray. Associations of biomarkers with overall survival and immune checkpoint inhibition (ICI) response were assessed.
Results
Neither CD8+ TIL counts nor PD‐L1 CPS alone were associated with overall survival; however, combined high TILs and CPS ≥ 1 were associated with improved survival compared to low TILS and CPS < 1 (18.5 vs. 10.0 months, p = 0.058). For patients treated with ICI ( n = 28), PD‐L1 CPS predicted ICI response more strongly than CD8+ TILs.
Conclusions
In R/M HNSCC, the combination of PD‐L1 CPS and CD8+ TILs is a stronger prognostic biomarker for overall survival compared with either biomarker alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Catherine T Haring, Joshua D Smith, Matthew E Spector, Paul L Swiecicki
Förderung
- NCI NIH HHS
- NIDCR NIH HHS
- NIH HHS
- University of Michigan
- National Institutes of Health
Zitieren
APA
Haring, C. T., Smith, J. D., Dermody, S. M., McHugh, J. B., Perry, W. R., Brummel, C., Spector, M. E., Brenner, J. C., & Swiecicki, P. L. (2025). Combined Tumor Infiltrating Lymphocytes and PD ‐ L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.28128
Vancouver
Haring CT, Smith JD, Dermody SM, McHugh JB, Perry WR, Brummel C, et al. Combined Tumor Infiltrating Lymphocytes and PD ‐ L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. 2025. doi:10.1002/hed.28128
BibTeX
@article{Haring2025,
author = {Haring, Catherine T and Smith, Joshua D and Dermody, Sarah M and McHugh, Jonathan B and Perry, William R and Brummel, Collin and Spector, Matthew E and Brenner, J Chad and Swiecicki, Paul L},
title = {Combined Tumor Infiltrating Lymphocytes and PD ‐ L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28128}
}
EUVIMED